Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Advanced Hepatocellular Cancer

Trial Name: Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

Protocol ID: Calgb 80802

Eligibility:

  • Patients must have pathologically or cytologically proven hepatocellular carcinoma.  Known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant is not allowed.
  • No prior adjuvant sorafenib or other Raf/VEGF inhibitors. 
  • Allografts are not allowed: No prior history of any allograft, including but not limited to liver and bone marrow transplants.
  • No known CNS tumors including brain metastases.
  • Significant history of cardiac disease is not allowed.
  • No history of bleeding diathesis.
  • Patients receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV) are excluded from the study because of possible pharmacokinetic interactions with sorafenib.
  • > 18 years of age.
  • Must meet required laboratory values.

Women of child-bearing potential and men must agree to use adequate contraception [hormonal or barrier method of birth control) prior to the initiation of protocol treatment, for the duration of the study participation, and 6 months after completing study treatment.

Enrollment: 480 Patients

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope sorafenib plus doxorubicin will be more useful against cancer compared to the commonly used sorafenib, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about sorafenib plus doxorubicin as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jan 18, 2013

Updated: Jan 18, 2013

« Return to Trials